kabutan

Immuno-Biological Lab, First Half Ordinary Profit Increases by 2.3 times, Jul-Sep Ordinary Profit Increases by 12 times

Thu Nov 13, 2025 3:30 pm JST Earnings

4570 Immuno-Biological Laboratories Co., Ltd. 【J-GAAP】

Earnings Report

Immuno-Biological Laboratories Co., Ltd. <4570> [TSE Growth] announced its financial results after the market closed on November 13th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) surged 2.3 times that of the same period last year, reaching 149 million yen. Progress toward the full-year plan of 240 million yen was 62.1%, also surpassing progress of 30.6% from the same period of the previous year.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to drop 37.2% from the same period last year to 91 million yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit surged 12 times that of the same period last year, reaching 92 million yen. The operating profit margin drastically improved from 7.9% in the same period last year to 32.1%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 365 13 30 26 2.9 24.0 Nov 2, 2023 J-GAAP
Apr - Sep, 2024 444 68 64 71 7.7 30.6 Nov 11, 2024 J-GAAP
Apr - Sep, 2025 485 142 149 141 15.2 62.1 Nov 13, 2025 J-GAAP
YoY +9.2% +108.8% +132.8% +98.6% +98.0%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 0 May 14, 2025 J-GAAP
Apr - Sep, 2025 Results 485 142 149 141 15.2 0 Nov 13, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 525 141 145 178 19.1 0 May 14, 2025 J-GAAP
Oct - Mar, 2025 Guidance 540 98 91 124 13.3 6 Nov 13, 2025 J-GAAP
YoY +2.9% -30.5% -37.2% -30.3% -30.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 816 104 125 186 20.1 0 May 14, 2024 J-GAAP
Mar, 2025 969 209 209 249 26.7 0 May 14, 2025 J-GAAP
Mar, 2026 Guidance 1,025 240 240 265 28.5 6 May 14, 2025 J-GAAP
YoY +5.8% +14.8% +14.8% +6.4% +6.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 215 17 8 20 2.2 7.9 Nov 11, 2024 J-GAAP
Oct - Dec, 2024 236 56 65 62 6.7 23.7 Feb 10, 2025 J-GAAP
Jan - Mar, 2025 289 85 80 116 12.5 29.4 May 14, 2025 J-GAAP
Apr - Jun, 2025 211 54 57 60 6.5 25.6 Aug 8, 2025 J-GAAP
Jul - Sep, 2025 274 88 92 81 8.7 32.1 Nov 13, 2025 J-GAAP
YoY +27.4% +417.6% +1,050.0% +305.0% +304.6%

Related Articles